Abstract
With the advent of immunomodulatory therapies and the HIV epidemic, the impact of JC Virus (JCV) on the public health system has grown significantly due to the increased incidence of Progressive Multifocal Leukoencephalopathy (PML). Currently, there are no pharmaceutical agents targeting JCV infection for the treatment and the prevention of viral reactivation leading to the development of PML. As JCV primarily reactivates in immunocompromised patients, it is proposed that the immune system (mainly the cellular-immunity component) plays a key role in the regulation of JCV to prevent productive infection and PML development. However, the exact mechanism of JCV immune regulation and reactivation is not well understood. Likewise, the impact of host factors on JCV regulation and reactivation is another understudied area. Here we discuss the current literature on host factor-mediated and immune factor-mediated regulation of JCV gene expression with the purpose of developing a model of the factors that are bypassed during JCV reactivation, and thus are potential targets for the development of therapeutic interventions to suppress PML initiation.
Similar content being viewed by others
References
Al-Tawfiq JA, Banda RW, Daabil RA, Dawamneh MF (2015) Progressive multifocal leukoencephalopathy (PML) in a patient with lymphoma treated with rituximab: A case report and literature review. J Infect Public Health 8(5):493–497
Amemiya K, Traub R, Durham L, Major EO (1992) Adjacent nuclear factor-1 and activator protein binding sites in the enhancer of the neurotropic JC virus. A common characteristic of many brain-specific genes J Biol Chem 267:14204–14211
Amirhaeri S, Wohlrab F, Major EO, Wells RD (1988) Unusual DNA structure in the regulatory region of the human papovavirus JC virus. J Virol 62:922–931
Astrom KE, Mancell EL, Richardson EPJ (1958) Progressive multifocal encephalopathy: a hitherto unrecognized complication of chronic lymphocytic leukemia and lymphoma. Brain. 81:99–111
Atwood WJ, Amemiya K, Traub R, Harms J, Major EO (1992) Interaction of the human polyomavirus, JCV, with human B-lymphocytes. Virology 190:716–723
Ault GS (1997) Activity of JC virus archetype and PML-type regulatory regions in glial cells. J. Gen. Virol. 78:163–169
Bacchetta F, Mathias A, Schluep M, Du Pasquier R (2017 Feb) Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: an intriguing coincidence. Mult Scler 23(2):300–303
Bateman OJ, Squires G, Thannhauser SJ (1945) Hodgkin’s disease associated with Schilder’s disease. Ann Intern Med 22:426–431
Baum S, Ashok A, Gee G, Dimitrova G, Querbes W, Jordan J, Atwood WJ (2003) Early events in the life cycle of JC virus as potential therapeutic targets for the treatment of progressive multifocal leukoencephalopathy. J Neuro-Oncol 9:32–37
Berger JR (2017) Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord 12:59–63
Berger JR, Chauhan A, Galey D, Nath A (2001) Epidemiological evidence and molecular basis of interactions between HIV and JC virus. J Neuro-Oncol 7:329–338
Berger JR, Miller CS, Mootoor Y, Avdiushko SA, Kryscio RJ, Zhu H (2006) JC virus detection in bodily fluids: clues to transmission. Clin Infect Dis 43:9–12
Bollag B, Prins C, Snyder EL, Frisque RJ (2000) Purified JC virus T and T’ proteins differentially interact with the retinoblastoma family of tumor suppressor proteins. Virology 274:165–178
Bowen L, Nath A, Smith B (2018) CNS immune reconstitution inflammatory syndrome. Handb Clin Neurol 152:167–176
Brooks BR, Walker DL (1984) Progressive multifocal encephalopathy. Neurol Clin 2:299–313
Bullock PA, Seo YS, Hurwitz J (1991) Initiation of simian virus 40 DNA synthesis in vitro. Mol Cell Biol 11:2350–2361
Carter CC, Onafuwa-Nuga A, McNamara LA, Riddell J 4th, Bixby D, Savona MR, Collins KL (2010) HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med 16:446–451
Cavanaugh JB, Greenbaum D, Marchall A, Rubinstein L (1959) Cerebral demyelination associated with disorder of thereticuloendothelial system. Lancet II:524–529
Chen NN, Change CF, Gallia GL, Kerr DA, Johnson EM, Krachmarov CP, Barr SM, Frisque RJ, Bollag B, Khalili K (1995) Cooperative action of cellular proteins YB-1 and Pur alpha with the tumor antigen of the human JC polyomavirus determines their interaction with the viral lytic control element. Proc Natl Acad Sci U S A 92:1087–1091
Chen NN, Kerr D, Chang CF, Honjo T, Khalili K (1997) Evidence for regulation of transcription and replication of the human neurotropic virus JCV genome by the human S(mu)bp-2 protein in glial cells. Gene 185:55–62
Chowdhury M, Taylor JP, Tada H, Rappaport J, Wong-Staal F, Amini S, Khalili K (1990) Regulation of the human neurotropic virus promoter by JCV-T antigen and HIV-1 tat protein. Oncogene 5:1737–1742
Chowdhury M, Taylor JP, Chang CF, Rappaport J, Khalili K (1992) Evidence that a sequence similar to TAR is important for induction of the JC virus late promoter by human immunodeficiency virus type 1 tat. J Virol 66:7355–7361
Chowdhury M, Kundu M, Khalili K (1993) GA/GC-rich sequence confers tat responsiveness to human neurotropic virus promoter, JCVL, in cells derived from central nervous system. Oncogene 8:887–892
Christensen E, Fog M (1955) A case of Schilder’s disease in an adult with remarks to etiology and pathogenesis. Acta Psychiatr Neurol Scand 30:141–154
Cinque P, Vago L, Dahl H et al (1996) Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus- associated opportunistic diseases of the central nervous system in HIV- infected patients. Aids 10:951–958
Cortese I, Muranski P, Enose-Akahata Y et al (2019) Pembrolizu- mab treatment for progressive multifocal leukoencephalopathy. N Engl J Med 380:1597–1605
Craigie M, Regan P, Otalora YL, Sariyer IK (2015) Molecular interplay between T-antigen and splicing factor, arginine/serine-rich 1 (SRSF1) controls JC virus gene expression in glial cells. Virol J. 12:196
Craigie M, Cicalese S, Sariyer IK (2018 Jun) Neuroimmune regulation of JC virus by intracellular and extracellular Agnoprotein. J NeuroImmune Pharmacol 13(2):126–142
Daniel DC, Kinoshita Y, Khan MA, Del Valle L, Khalili K, Rappaport J, Johnson EM (2004) Internalization of exogenous human immunodeficiency virus-1 protein, tat, by KG-1 oligodendroglioma cells followed by stimulation of DNA replication initiated at the JC virus origin. DNA Cell Biol 23:858–867
Del Valle L, Baehring J, Lorenzana C, Giordano A, Khalili K, Croul S (2001) Expression of a human polyomavirus oncoprotein and tumour suppressor proteins in medulloblastomas. Mol Pathol 54:331–337
D'Souza A, Wilson J, Mukherjee S, Jaiyesimi I (2010 Feb) Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia: a report of three cases and review of the literature. Clin Lymphoma Myeloma Leuk 10(1):E1–E9
Dugan AS, Gasparovic ML, Atwood WJ (2008) Direct correlation between sialic acid binding and infection of cells by two human polyomaviruses (JC virus and BK virus). J Virol 82:2560–2564
Elphick GF, Querbes W, Jordan JA, Gee GV, Eash S, Manley K, Dugan A, Stanifer M, Bhatnagar A, Kroeze WK, Roth BL, Atwood WJ (2004) The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 19:1380–1383
Enam S, Sweet TM, Amini S, Khalili K, Del Valle L (2004) Evidence for involvement of transforming growth factor beta1 signaling pathway in activation of JC virus in human immunodeficiency virus 1-associated progressive multifocal leukoencephalopathy. Arch Pathol Lab Med 128:282–291
Engel S, Herger T, Mancini R, Herzog F, Kartenbeck J, Hayer A, Helenius A (2011) Role of endosomes in simian virus 40 entry and infection. J Virol 85:4198–4211
Engelhardt B, Kappos L (2008) Natalizumab: targeting alpha4-integrins in multiple sclerosis. Neurodegener Dis 5:16–22
Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, Wingfield P, Gallo RC (1993) Release, uptake, and effects of extracellular human immunodeficiency virus type 1 tat protein on cell growth and viral transactivation. J Virol 67:277–287
Fabis-Pedrini MJ, Xu W, Burton J, Carroll WM, Kermode AG (2016 Mar) Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment. J Clin Neurosci 25:145–147
Fairman MP, Stillman B (1988) Cellular factors required for multiple stages of SV40 DNA replication in vitro. EMBO J 7:1211–1218
Felli V, Di Sibio A, Anselmi M, Gennarelli A, Sucapane P, Splendiani A, Catalucci A, Marini C, Gallucci M (2014) Progressive multifocal leukoencephalopathy following treatment with rituximab in an HIV-negative patient with non-Hodgkin lymphoma. A case report and literature review. Neuroradiol J 27(6):657–664
Ferenczy MW, Marshall LJ, Nelson CDS, Atwood WJ, Nath A, Khalili K, Major EO (2012) Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microb Rev 25:471–505
Fleischmann RM (2009) Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum 60(11):3225–3228
Fournier A, Martin-Blondel G, Lechapt-Zalcman E, Dina J, Kazemi A, Verdon R, Mortier E, de La Blanchardière A (2017) Immune reconstitution inflammatory syndrome unmasking or worsening AiDS-related progressive multifocal leukoencephalopathy: a literature review. Front Immunol 8:577
Freim Wahl SG, Folvik MR, Torp SH (2007) Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature. Clin Neuropathol 26(2):68–73
Frisque RJ (1983) Regulatory sequences and virus-cell interactions of JC virus. Prog Clin Biol Res 105:41–59
Gadzia J, Turner J (2010) Progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab. J Drugs Dermatol 9(8):1005–1009
Gagne Brosseau MS, Stobbe G, Wundes A (2016) Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay. Neurology. 86(5):484–486
Ge H, Manley JL (1990) A protein factor, ASF, controls cell-specific alternative splicing of SV40 early pre-mRNA in vitro. Cell 13:25–34
Gheuens S, Bord E, Kesari S et al (2011) Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome. J Virol 85(14):7256–7263
Gheuens S, Smith DR, Wang X, Alsop DC, Lenkinski RE, Koralnik IJ (2012) Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology. 78(18):1390–1393
Hallervorden J (1930) Eigennartige und nicht rubizierbare Prozesse. In: Bumke O (ed) Handbuch der Geiteskranhetinen Springer. Germany, Berlin, pp 1063–1107
Havla J, Berthele A, Kümpfel T, Krumbholz M, Jochim A, Kronsbein H, Ryschkewitsch C, Jensen P, Lippmann K, Hemmer B, Major E, Hohlfeld R (2013) Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab "infusion group". Mult Scler 19(9):1213–1215
Himedan M, Camelo-Piragua S, Mills EA, Gupta A, Aburashed R, Mao-Draayer Y (2017) Pathologic findings of chronic PML-IRIS in a patient with prolonged PML survival following Natalizumab treatment. J Investig Med High Impact Case Rep 5(3):2324709617734248
Houff SA, Berger JR (2008) The bone marrow, B cells, and JC virus. J Neuro-Oncol 14:341–343
Houff SA, Major EO, Katz DA, Kufta CV, Sever JL, Pittaluga S, Roberts JR, Gitt J, Saini N, Lux W (1988) Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 318:301–305
Ikegaya H, Iwase H (2004) Trial for the geographical identification using JC viral genotyping in Japan. Forensic Sci Int 139:169–172
Isidoro L, Pires P, Rito L, Cordeiro G (2014) Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab. BMJ Case Rep. 8:2014
Jing D, Oelschlaegel U, Ordemann R, Hölig K, Ehninger G, Reichmann H, Ziemssen T, Bornhäuser M (2010) CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. Bone Marrow Transplant 45:1489–1496
Kerr D, Chang CF, Chen N, Gallia G, Raj G, Schwartz B, Khalili K (1994) Transcription of a human neurotropic virus promoter in glial cells: effect of YB-1 on expression of the JC virus late gene. J Virol 68:7637–7643
Knowles WA, Pipkin P, Andrews N, Vyse A, Minor P, Brown DW, Miller E (2003) Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 71:115–123
Koralnik IJ (2019 Apr 25) Can immune checkpoint inhibitors keep JC virus in check? N Engl J Med 380(17):1667–1668
Kothary N, Diak IL, Brinker A, Bezabeh S, Avigan M, Dal PG (2011 Sep) Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 65(3):546–551
Krumbholz M, Meinl I, Kumpfel T, Hohlfeld R, Meinl E (2008) Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 71:1350–1354
Kumar D, Bouldin TW, Berger RG (2010 Nov) A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab. Arthritis Rheum 62(11):3191–3195
Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D (2005 Jul 28) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353(4):375–381
Lebwoh M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D, Efalizumab Study Group (2003) A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349:2004–2013
Lee SH, Hurwitz J (1990) Mechanism of elongation of primed DNA by DNA polymerase delta, proliferating cell nuclear antigen, and activator 1. Proc Natl Acad Sci U S A 87:5672–5676
Lindå H, von Heijne A, Major EO, Ryschkewitsch C, Berg J, Olsson T, Martin C (2009) Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 361(11):1081–1087
Lindberg RL, Achtnichts L, Hoffmann F, Kuhle J, Kappos L (2008) Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 194:153–164
Lipsky JJ (1996) Mycophenolate mofetil. Lancet 348:1357–1359
Liu CK, Wei G, Atwood WJ (1998) Infection of glial cells by the human polyomavirus JC is mediated by N-linked glycoprotein containing terminal alpha (2-6)-linked sialic acids. J Virol 72:4643–4649
Maginnis MS, Haley SA, Gee GV, Atwood WJ (2010) Role of N-linked glycosylation of the 5-HT2A receptor in JC virus infection. J Virol 84:9677–9684
Major EO (2010) Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 61:35–47
Major EO, Neel JV (1998) The JC and BK human polyoma viruses appear to be recent introductions to some south American Indian tribes: there is no serological evidence of cross-reactivity with the simian polyoma virus SV40. Proc Natl Acad Sci U S A 95:15525–15530
Major EO, Amemiya K, Elder G, Houff SA (1990) Glial cells of the human developing brain and B cells of the immune system share a common DNA binding factor for recognition of the regulatory sequences of the human polyomavirus. JCV J Neurosci Res 27:461–471
Major EO, Amemiya K, Elder G, Tornatore CS, Houff SA, Berger JR (1992) Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC-virus induced demyelinating disease of the human brain. Clin Microbiol Rev 5:49–73
Marshall LJ, Dunham L, Major EO (2010) Transcription factor Spi-B binds unique sequences present in the tandem repeat promoter/ enhancer of JC virus and supports viral activity. J. Gen. Virol. 91:3042–3052
Martin-Blondel G, Bauer J, Cuvinciuc V, Uro-Coste E, Debard A, Massip P, Delisle MB, Lassmann H, Marchou B, Mars LT, Liblau RS (2013 Sep 10) In situ evidence of JC virus control by CD8+ T cells in PML–IRIS during HIV infection. Neurology. 81(11):964–970
Martin-Blondel G, Bauer J, Uro-Coste E, Biotti D, Averseng-Peaureaux D, Fabre N, Dumas H, Bonneville F, Lassmann H, Marchou B, Liblau RS, Brassat D (2015 Mar) Therapeutic use of CCR5 antagonists is supported by strong expression of CCR5 on CD8(+) T cells in progressive multifocal leukoencephalopathy-associated immune reconstitution inflammatory syndrome. Acta Neuropathol 129(3):463–465
Mázló M, Tariska I (1982) Are astrocytes infected in progressive multifocal leukoencephalopathy? Acta Neuropathol 56:45–51
McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825–2833
Monaco MC, Atwood WJ, Gravell M, Tornatore CS, Major EO (1996) JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J Virol 70:7004–7012
Müller M, Wandel S, Colebunders R, Attia S, Furrer H (2010 Apr) Egger M; IeDEA southern and Central Africa. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 10(4):251–261
Nesper J, Smith RW, Kautz AR, Sock E, Wegner M, Grummt F, Nasheuer HP (1997) A cell-free replication system for human polyomavirus JC DNA. J Virol 71:7421–7428
Neu U, Maginnis M, Palma A, Ströh LJ, Nelson CDS, Feizi T, Atwood WJ, Stehle T (2011) Structure-function analysis of the human JC polyomavirus establishes the LSTc pentasaccharide as a functional receptor motif. Cell Host Microb 8:309–319
Nukuzuma S et al (2010) Efficient propagation of progressive multifocal leukoencephalopathy-type JC virus in COS-7-derived cell lines stably expressing tat protein of human immunodeficiency virus type 1. Microbiol Immunol 54:758–762
Okada Y, Endo S, Takahashi H, Sawa H, Umemura T, Nagashima K (2001) Distribution and function of JCV agnoprotein. J Neuro-Oncol 7:302–306
Otlu O, De Simone FI, Otalora YL, Khalili K, Sariyer IK (2014) The agnoprotein of polyomavirus JC is released by infected cells: evidence for its cellular uptake by uninfected neighboring cells. Virology 468–470:88–95
Parikh A, Stephens K, Major E, Fox I, Milch C, Sankoh S, Lev MH, Provenzale JM, Shick J, Patti M, McAuliffe M, Berger JR, Clifford DB (2018) A Programme for risk assessment and minimisation of progressive multifocal leukoencephalopathy developed for Vedolizumab clinical trials. Drug Saf. https://doi.org/10.1007/s40264-018-0669-8
Paues J, Vrethem M (2010) Fatal progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma treated with rituximab. J Clin Virol 48(4):291–293
Petito CK, Cash KS (1992) Blood-brain barrier abnormalities in the acquired immunodeficiency syndrome: immunohistochemical localization of serum proteins in postmortem brain. Ann Neurol 32:658–666
Phan-Ba R, Lommers E, Tshibanda L, Calay P, Dubois B, Moonen G, Clifford D, Belachew S (2012) MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy. J Neurol Neurosurg Psychiatry 83(2):224–226
Pho MT, Ashok A, Atwood WJ (2000) JC virus enters human glial cells by clathrin-dependent receptor-mediated endocytosis. J Virol 74:2288–2292
Puri V, Chaundhry N, Gulati P, Patel N, Tatke M, Sinha S (2010) Progressive multifocal leukoencephalopathy in a patient with idiopathic CD4+ T lymphocytopenia. Neurol India 58:118–121
Querbes W, Benmerah A, Tosoni D, Di Fiore PP, Atwood WJ (2004) A JC virus-induced signal is required for infection of glial cells by a clarthin- and eps15-dependent pathway. J Virol 78:250–256
Querbes W, O’Hara BA, Williams G, Atwood WJ (2006) Invasion of host cells by JC virus identifies a novel role for caveolae in endosomal sorting of noncaveolar ligands. J Virol 80:9402–9413
Ranganathan PN, Khalili K (1993) The transcriptional enhancer element, kappa B, regulates promoter activity of the human neurotrophic virus, JCV, in cells derived from the CNS. Nucleic Acids Res 21:1959–1964
Rauer S, Marks R, Urbach H et al (2019) Treatment of progressive multifocal leukoencephalopathy with pembrolizumab. N Engl J Med 380:1676–1677
Ravichandran V, Sabath BF, Jensen PN, Houff SA, Major EO (2006) Interactions between c-Jun, nuclear factor 1, and JC virus promoter sequences: implications for viral tropism. J Virol 80:10506–10513
Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435–445
Rice GP, Hartung HP, Calabresi PA (2005) Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology. 64:1336–1342
Richardson EP Jr (1961) Progressive multifocal leukoencephalopathy. N Engl J Med 265:815–823
Rudnicka D, Oszmiana A, Finch DK, Strickland I, Schofield DJ, Lowe DC, Sleeman MA, Davis DM (2013) Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity. Blood. 121(23):4694–4702
Sano Y, Nakano Y, Omoto M, Takao M, Ikeda E, Oga A, Nakamichi K, Saijo M, Maoka T, Sano H, Kawai M, Kanda T (2015) Rituximab-associated progressive multifocal leukoencephalopathy derived from non-Hodgkin lymphoma: neuropathological findings and results of mefloquine treatment. Intern Med 54(8):965–970
Saribas AS, Ozdemir A, Lam C, Safak M (2010) JC virus-induced progressive multifocal leukoencephalopathy. Future Virol 5:313–323
Saribas AS, White MK, Safak M (2018 Mar) Structure-based release analysis of the JC virus agnoprotein regions: a role for the hydrophilic surface of the major alpha helix domain in release. J Cell Physiol 233(3):2343–2359
Sariyer, I.K., Khalili, K. (2011) Regulation of human neurotropic JC virus replication by alternative splicing factor SF2/ASF in glial cells. PLoS one. 2011 Jan 31;6(1):e14630
Sariyer R, De-Simone FI, Gordon J, Sariyer IK (2016) Immune suppression of JC virus gene expression is mediated by SRSF1. J Neuro-Oncol 22:597–606
Schwab N, Ulzheimer JC, Fox RJ, Schneider-Hohendorf T, Kieseier BC, Monoranu CM, Staugaitis SM, Welch W, Jilek S, Du Pasquier RA, Brück W, Toyka KV, Ransohoff RM, Wiendl H (2012a Feb 14) Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control. Neurology. 78(7):458–467
Schwab N, Höhn KG, Schneider-Hohendorf T, Metz I, Stenner MP, Jilek S, Du Pasquier RA, Gold R, Meuth SG, Ransohoff RM, Brück W, Wiendl H (2012b Mar) Immunological and clinical consequences of treating a patient with natalizumab. Mult Scler 18(3):335–344
Shivakumar CV, Das GC (1994) Biochemical and mutational analysis of the polyomavirus core promoter: involvement of nuclear factor-1 in early promoter function. J Gen Virol 75:1281–1290
Sierra Morales F, Illingworth C, Lin K, Rivera Agosto I, Powell C, Sloane JA, Koralnik IJ (2017 Oct) PML-IRIS in an HIV-2-infected patient presenting as Bell's palsy. J Neuro-Oncol 23(5):789–792
Sikkema T, Schuiling WJ, Hoogendoorn M (2013 Jan) Progressive multifocal leukoencephalopathy during treatment with rituximab and CHOP chemotherapy in a patient with a diffuse large B-cell lymphoma. BMJ Case Rep 25:2013
Stettner MR, Nance JA, Wright CA, Kinoshita Y, Kim WK, Morgello S, Rappaport J, Khalili K, Gordon J, Johnson EM (2009) SMAD proteins of oligodendroglial cells regulate transcription of JC virus early and late genes coordinately with the tat protein of human immunodeficiency virus type 1. J. Gen. Virol. 90:2005–2014
Stoppe M, Thomä E, Liebert UG, Major EO, Hoffmann KT, Claßen J, Then BF (2014 May) Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis. J Neurol 261(5):1021–1024
Suzuki T, Orba Y, Okada Y, Sunden Y, Kimura T, Tanaka S, Nagashima K, Hall WW, Sawa H (2010 Mar 12) The human polyoma JC virus agnoprotein acts as a viroporin. LoS Pathog 6(3):e1000801
Tada H, Khalili K (1992) A novel sequence-specific DNA-binding protein, LCP-1, interacts with single-stranded DNA and differentially regulates early gene expression of the human neurotropic JC virus. J Virol 66:6885–6892
Tada H, Rappaport J, Lashgari M, Amini S, Wong-Staal F, Khalili K (1990) Trans-activation of the JC virus late promoter by the tat protein of type 1 human immunodeficiency virus in glial cells. Proc Natl Acad Sci U S A 87:3479–3483
Tavis JE, Trowbridge PW, Frisque RJ (1994) Converting the JCV T antigen Rb binding domain to that of SV40 does not alter JCV’s limited transforming activity but does eliminate viral viability. Virology 199:384–392
Taylor JP, Cupp C, Diaz A, Chowdhury M, Khalili K, Jimenez SA, Amini S (1992) Activation of expression of genes coding for extracellular matrix proteins in tat-producing glioblastoma cells. Proc Natl Acad Sci U S A 89:9617–9621
Tornatore C, Berger JR, Houff SA, Curfman B, Meyers K, Winfield D, Major EO (1992) Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy. Ann Neurol 31:454–462
Tsurimoto T, Melendy T, Stillman B (1990) Sequential initiation of lagging and leading strand synthesis by two different polymerase complexes at the SV40 DNA replication origin. Nature 346:534–539
Uleri E, Beltrami S, Gordon J, Dolei A, Sariyer IK (2011) Extinction of tumor antigen expression by SF2/ASF in JCV-transformed cells. Genes Cancer 2:728–736
Uphaus T, Oberwittler C, Groppa S, Zipp F, Bittner S (2017 Dec) Disease reactivation after switching from natalizumab to daclizumab. J Neurol 264(12):2491–2494
Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, Rutgeerts P (2005 Jul 28) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353(4):362–368
Vendrely A, Bienvenu B, Gasnault J, Theibault JB, Salmon D, Gray F (2005) Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol 109:449–455
Waggoner J, Martinu T, Palmer SM (2009 Apr) Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. J Heart Lung Transplant 28(4):395–398
Warsch S, Hosein PJ, Morris MI, Teomete U, Benveniste R, Chapman JR, Lossos IS (2012 Aug) Progressive multifocal leukoencephalopathy following treatment with bendamustine and rituximab. Int J Hematol 96(2):274–278
Wegner M, Drolet DW, Rosenfeld MG (1993) Regulation of JC virus by the POU-domain transcription factor Tst-1: implications for progressive multifocal leukoencephalopathy. Proc Natl Acad Sci U S A 90:4743–4747
Weinberg DH, Collins KL, Simancek P, Russo A, Wold MS, Virshup DM, Kelly TJ (1990) Reconstitution of simian virus 40 DNA replication with purified proteins. Proc Natl Acad Sci U S A 87:8692–8696
White MK, Khalili K (2006) Interaction of retinoblastoma protein family members with large T-antigen of primate polyomaviruses. Oncogene 25:5286–5293
Wiley CA, Grafe M, Kennedy C, Nelson JA (1988) Human immunodeficiency virus and JC virus in acquired immune deficiency syndrome patients with progressive multifocal leukoencephalopathy. Acta Neuropathol 76:338–346
Windpessl M, Burgstaller S, Kronbichler A, Pieringer H, Kalev O, Karrer A, Wallner M, Thaler J (2018) Progressive multifocal leukoencephalopathy following combined rituximab-based immune-chemotherapy for post-transplant lymphoproliferative disorder in a renal transplant recipient: a case report. Transplant Proc 50(3):881–883
Winkleman NW, Moore MT (1941) Lymphogranulomatosis (Hodgkin’s disease) of the nervous system. Arch Neurol Psychol 45:304–318
Wüthrich C, Kesari S, Kim WK, Williams K, Gelman R, Elmeric D, De Girolami U, Joseph JT, Hedley-Whyte T, Koralnik IJ (2006) Characterization of lymphocytic infiltrate in progressive multifocal leukoencephalopathy: co-localization of CD8(+) T cells with JCV-infected glial cells. J Neuro-Oncol 12:116–128
Yadav A, Collman RG (2009) CNS inflammation and macrophage/microglial biology associated with HIV-1 infection. J NeuroImmune Pharmacol 4:430–447
Yokoyama H, Watanabe T, Maruyama D, Kim SW, Kobayashi Y, Tobinai K (2008) Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature. Int J Hematol 88(4):443–447
Funding
This work was made possible by grants awarded by NIH to IKS (AI101192).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare no conflict of interest.
Ethical Approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Khalili, A., Craigie, M., Donadoni, M. et al. Host-Immune Interactions in JC Virus Reactivation and Development of Progressive Multifocal Leukoencephalopathy (PML). J Neuroimmune Pharmacol 14, 649–660 (2019). https://doi.org/10.1007/s11481-019-09877-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11481-019-09877-8